Piper Sandler Reiterates Neutral Rating on Pacific Biosciences of California, Inc. (PACB)

Market Context

Pacific Biosciences of California, Inc. operates in the Healthcare sector. The stock currently trades at $2.43 with a market capitalization of $652.1M. The stock has gained 21.5% over the past 52 weeks.

Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pacific Biosciences of California, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Pacific Biosciences of California, Inc.

Among the 10 most recent ratings: 1 Buy, 5 Hold, 4 Sell.

Date	Firm	Rating	Price Target
Nov 05, 2026	Piper Sandler	Neutral	N/A
Nov 05, 2026	Barclays	Underweight	N/A
May 11, 2026	Barclays	Underweight	N/A
Apr 14, 2026	Barclays	Underweight	N/A
Mar 06, 2026	Barclays	Underweight	N/A

Related Tools: Analyst Ratings Dashboard | View PACB Stock Page